Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128595 | 0.80 | GPR119 (0.39) | MEN1KMT2A | |
| SCHEMBL6125551 | 0.75 | GPR119 (0.35) | KDM1AOPRK1SMN1; SMN2 | |
| SCHEMBL461225 | 0.73 | DRD2 (0.34) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12490134 | 0.63 | FAAH (0.47) | MAPTPOLBOPRK1MEN1KMT2A | |
| SCHEMBL12506061 | 0.61 | MAPT (0.49) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL14723550 | 0.59 | GPR119 (0.40) | OPRK1 | |
| SCHEMBL8614390 | 0.59 | GPR119 (0.38) | OPRK1 | |
| SCHEMBL12490078 | 0.58 | GPR119 (0.39) | OPRK1 | |
| SCHEMBL12490728 | 0.58 | GPR119 (0.68) | MAPTOPRK1 | |
| SCHEMBL22630178 | 0.58 | LMNA (0.45) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |